How to translate preclinical data into investor language
Most founders present the data they have. Investors evaluate the data they need. Here is the framework for closing that gap before the first investor meeting.
Most early-stage biotech founders approach investor conversations with the data they have. What investors evaluate is the data they need. The gap between these two is rarely a scientific problem: the experiments exist, the results are real, and the findings are often genuinely promising. The problem is a structural one: the data was generated to answer scientific questions, not to retire the specific risks that stand between the asset and a pharma exit. Translating preclinical data into investor language means rebuilding the evidence map backwards, from the exit to the experiment.
Why the scientific presentation fails in investor meetings
Biotech investors do not evaluate data the way a reviewer does. They evaluate data the way a pharma business development team does: against the specific evidentiary requirements of a clinical development programme and the transaction economics of a deal. The question they are answering is not whether the science is interesting. It is whether the data package, as it stands today, is sufficient to de-risk the asset to the next valuation bracket, and what it would take to close the gap if it is not.
A scientific presentation of preclinical data organises findings by experiment, by chronology, or by biological mechanism. It leads with the most interesting result, supports it with methodological detail, and situates it in the context of the existing literature. This is exactly the right structure for a peer review or a grant application. It is the wrong structure for an investor meeting.
The single most common failure mode in investor presentations of preclinical data is presenting strength where it exists while leaving weakness implicit. A deck that leads with potent efficacy data in a validated disease model, then quietly omits the safety and stability profile, signals to an experienced investor that the safety and stability profile is a problem. Silence on a critical data dimension is not neutral. It is informative.
The funding environment makes this more consequential than ever. In Q1 2026, J.P. Morgan noted that venture capital is prioritising biotechs with established data packages, de-risked development, and nearer-term catalysts, reinforcing the funding gap between early-stage and later-stage assets. The standard for what counts as a credible preclinical package has risen. The translation work described in this article is not optional preparation. It is the price of entry to a serious investor conversation.
Silence on a critical data dimension is not neutral. An investor who notices what is missing from a preclinical package has learned something the founder did not intend to communicate.
The Evidence Gap Map: Leonardo Biondi's framework for preclinical data translation
The Evidence Gap Map is a four-step framework for translating preclinical data into investor language by working backwards from the exit rather than forwards from the experiment. It produces a structured comparison between what a pharma business development team requires and what the current data package contains, with each gap classified by its commercial significance and the effort required to close it.
The starting point is not the data. It is the exit. Specifically: which pharma company is the most plausible acquirer or licensee for this asset, and what evidence package would that company's business development team require to initiate a serious conversation with their internal R&D?
In Q1 2026, with IPO activity near historic lows in Europe, pharma acquisition remains the most realistic exit path for the majority of early-stage European biotech assets. Centessa Pharmaceuticals was acquired by Eli Lilly for £4.6 billion in Q1 2026. Dark Blue Therapeutics was acquired by Amgen for £626 million in the same quarter. The acquirers in both cases were evaluating the same evidence dimensions that the Evidence Gap Map is designed to map.
Working backwards from that question produces a structured list of data requirements across every dimension the licensee will evaluate: efficacy in a clinically relevant model, safety and tolerability profile, pharmacokinetics and pharmacodynamics, stability and manufacturability, biomarker strategy, and regulatory pathway clarity. This list is the investor's implicit checklist: not always stated explicitly in the investor meeting, but always operative in the investment committee discussion that follows.
The four steps of the Evidence Gap Map:
Step 1: Define the exit scenario
Name the most plausible acquirer or licensee, identify the indication and modality that fits their pipeline strategy, and describe what a transaction would look like at the next value inflection point.
Step 2: Map the required evidence landscape
Working backwards from the licensee's due diligence requirements, build the complete list of data a pharma BD team needs across efficacy, safety, PK/PD, manufacturability, biomarker, and regulatory dimensions.
Step 3: Conduct the gap analysis
Compare the required evidence landscape against the existing data package, dimension by dimension. The gaps are the commercial risk. The strong dimensions are the investment thesis.
Step 4: Classify each gap
Assign each gap to one of three categories: closable with existing data that has not yet been packaged, closable with a defined experiment at a defined cost, or representing genuine scientific uncertainty that must be disclosed and priced.
Once the required data landscape is defined, the gap analysis maps what exists against what is needed, and categorises each gap by its commercial significance and de-risking potential. Not all gaps are equal. A gap in efficacy data in the primary indication is a fundamental problem that reprices the entire asset. A gap in stability data for a specific formulation may be addressable with a defined experiment in a defined timeframe at a defined cost. The translation from scientific to investor language requires making this distinction explicit. Every experiment that closes a meaningful gap is a de-risking event. Every de-risking event is a value inflection point. The Evidence Gap Map makes this chain visible.
The data profile that investors and pharma BD teams actually build
Efficacy data is almost always the most developed in an early-stage biotech asset: founders invest disproportionately in the experiments that demonstrate that the mechanism works. These experiments answer scientific questions. They do not always produce the de-risking evidence that moves an asset from one valuation bracket to the next. Safety data is frequently incomplete. Stability and manufacturability data is often absent entirely. PK/PD profiling is sometimes present for the primary species but not for the secondary species required for IND-enabling work. Biomarker data, which would allow identification of the patient population most likely to respond, is frequently underdeveloped relative to its importance in a pharma licensing conversation.
This unevenness is not a failure of scientific planning. It is a natural consequence of how academic and early-stage research is funded and structured. Grants fund the experiments that answer the most interesting scientific questions. The most interesting scientific question is almost always about mechanism and efficacy, not about the safety margin or the manufacturability of the final formulation. The gap analysis that backward induction reveals is therefore not a critique of the science. It is a map of what was funded versus what a commercial partner requires.
The data map of a promising early-stage asset almost always has the same shape: rich in efficacy, thinner in safety, sparse in manufacturability. The investor's job is to price that shape. The founder's job is to present it honestly and explain how the gap will be closed.
What to do with the gaps
A gap analysis produces three categories of finding, each requiring a different response in the investor presentation.
Gaps closable with existing data
Sometimes the data exists but has not been included in the investor package because it was not considered relevant to the scientific narrative. A stability study conducted for a different purpose, a safety observation documented in a methods section, a PK profile measured as a secondary endpoint. Identifying these and integrating them into the investor presentation is the simplest form of translation work.
Gaps closable with a defined experiment
The most valuable thing a founder can present to an investor is not a complete data package, it is a complete data package with a credible plan for closing the remaining gaps. A specific experiment, a defined timeline, a realistic cost estimate, and a clear statement of what the result would need to show to retire the risk. This transforms a weakness into a milestone, and a milestone is exactly what investors fund.
Gaps representing genuine scientific uncertainty
Some gaps cannot be closed quickly or cheaply because the underlying question is genuinely difficult. Presenting these honestly, with an accurate characterisation of what is known and what is not, is both the ethically correct approach and the strategically smart one. Investors who discover undisclosed uncertainty during due diligence do not forget it. Honestly presented uncertainty, framed with a credible view on the risk, can be priced.
The language of risk retirement, not scientific achievement
The final step in the translation is linguistic. The same preclinical data point can be described in scientific language or in investor language, and the two descriptions serve entirely different functions in a biotech fundraising context.
Scientific language
"In a murine model of disease X, compound Y demonstrated 78% tumour growth inhibition at a dose of 10 mg/kg with an acceptable tolerability profile at doses up to 30 mg/kg in a 28-day repeat-dose study."
Investor language
"The efficacy data in the primary model, combined with the safety margin demonstrated in the 28-day study, removes the primary scientific uncertainty that was preventing a serious BD conversation with the three pharma companies we have identified as the most likely licensees. The remaining risk is the PK profile in a non-rodent species, which is the specific experiment this round of capital is designed to fund."
The scientific description is accurate. The investor description is actionable. It tells the investor what risk has been retired, what risk remains, and what the capital will do to address it. That is the structure of a fundable investment case.
Like what you're reading?
Subscribe for more strategic notes on biotech and venture design.
Frequently asked questions
The Evidence Gap Map is the tool for navigating between the data you have and the data the investor needs: identifying which milestones move valuation, which de-risking experiments are worth funding now, and which gaps must be disclosed before the first serious investor conversation begins.
Book a 30-minute call